Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
mardi, octobre 13
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Immunovant Inc
IMVT
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$28.90
-0.58
-1.97%
Dern. MÀJ: Oct 13, 3:13 PM
$29.00
-0.48
-1.63%
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Privacy Manager
Immunovant Financials
Immunovant (IMVT) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Immunovant Q1 EPS $(0.75) Misses $(0.61) Estimate
Immunovant (NASDAQ:IMVT) reported quarterly losses of $(0.75) per share which missed the analyst consensus estimate of $(0.61) by 22.95 percent. This is a 5.63 percent decrease over losses of $(0.71) per share from the
Benzinga Newsdesk
These Analysts Increase Their Forecasts On Immunovant After Q4 Results
Immunovant (NASDAQ:IMVT) reported a Q4 loss of 73 cents/share, missing estimates of 60 cents. R&D expenses rose to $142.3 million. Analysts adjust price targets.
Avi Kapoor
Immunovant Stock Surges Despite Disappointing Earnings Miss
Immunovant Inc (NASDAQ: IMVT) shares are trading higher Wednesday despite posting a wider-than-expected fourth‑quarter loss.
Evette Mitkov
Earnings Scheduled For May 20, 2026
Benzinga Insights
PRO
Immunovant Q4 EPS $(0.73) Misses $(0.60) Estimate
Immunovant (NASDAQ:IMVT) reported quarterly losses of $(0.73) per share which missed the analyst consensus estimate of $(0.60) by 21.67 percent. This is a 14.06 percent decrease over losses of $(0.64) per share from the
Benzinga Newsdesk
PRO
Immunovant Q3 EPS $(0.61) Beats $(0.71) Estimate
Immunovant (NASDAQ:IMVT) reported quarterly losses of $(0.61) per share which beat the analyst consensus estimate of $(0.71) by 13.72 percent. This is a 19.74 percent increase over losses of $(0.76) per share from the
Benzinga Newsdesk
